Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Experience From an Area in Which Betel Nut Chewing Is Popular

Peter Mu Hsin Chang, Yao Yu Hsieh, Ming Huang Chen, Cheng Hwai Tzeng, Pen Yuan Chu, Shyue Yih Chang, Po Min Chen, Muh Hwa Yang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalJournal of the Chinese Medical Association
Volume73
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Areca
Mastication
Cisplatin
Drug Therapy
Group Psychotherapy
Therapeutics
Survival
Neutropenia
Fever
Cetuximab
Carcinoma, squamous cell of head and neck
Safety
Infection

Keywords

  • Betel nut
  • Cetuximab
  • Head and neck cancer
  • Taxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma : Experience From an Area in Which Betel Nut Chewing Is Popular. / Chang, Peter Mu Hsin; Hsieh, Yao Yu; Chen, Ming Huang; Tzeng, Cheng Hwai; Chu, Pen Yuan; Chang, Shyue Yih; Chen, Po Min; Yang, Muh Hwa.

In: Journal of the Chinese Medical Association, Vol. 73, No. 6, 06.2010, p. 292-299.

Research output: Contribution to journalArticle

Chang, Peter Mu Hsin ; Hsieh, Yao Yu ; Chen, Ming Huang ; Tzeng, Cheng Hwai ; Chu, Pen Yuan ; Chang, Shyue Yih ; Chen, Po Min ; Yang, Muh Hwa. / Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma : Experience From an Area in Which Betel Nut Chewing Is Popular. In: Journal of the Chinese Medical Association. 2010 ; Vol. 73, No. 6. pp. 292-299.
@article{4e5aba762fe14b8fb9ed89a8104a82f4,
title = "Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular",
abstract = "Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54{\%} and disease control rate [CR + PR + stable disease (SD)] was 62{\%}. In the cisplatin-failure therapy group, the overall response was 16.7{\%} and disease control rate was 50{\%}. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23{\%} in the first-line group, 50{\%} in the cisplatin-failure group), followed by neutropenia (23{\%} in the first-line group, 25{\%} in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.",
keywords = "Betel nut, Cetuximab, Head and neck cancer, Taxane",
author = "Chang, {Peter Mu Hsin} and Hsieh, {Yao Yu} and Chen, {Ming Huang} and Tzeng, {Cheng Hwai} and Chu, {Pen Yuan} and Chang, {Shyue Yih} and Chen, {Po Min} and Yang, {Muh Hwa}",
year = "2010",
month = "6",
doi = "10.1016/S1726-4901(10)70064-2",
language = "English",
volume = "73",
pages = "292--299",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

T2 - Experience From an Area in Which Betel Nut Chewing Is Popular

AU - Chang, Peter Mu Hsin

AU - Hsieh, Yao Yu

AU - Chen, Ming Huang

AU - Tzeng, Cheng Hwai

AU - Chu, Pen Yuan

AU - Chang, Shyue Yih

AU - Chen, Po Min

AU - Yang, Muh Hwa

PY - 2010/6

Y1 - 2010/6

N2 - Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.

AB - Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.

KW - Betel nut

KW - Cetuximab

KW - Head and neck cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=77954285101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954285101&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(10)70064-2

DO - 10.1016/S1726-4901(10)70064-2

M3 - Article

VL - 73

SP - 292

EP - 299

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 6

ER -